All Title Author
Keywords Abstract


Interleukin (IL)-6 and IL-10 Are Up Regulated in Late Stage Trypanosoma brucei rhodesiense Sleeping Sickness

DOI: 10.1371/journal.pntd.0003835

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Sleeping sickness due to Trypanosoma brucei rhodesiense has a wide spectrum of clinical presentations coupled with differences in disease progression and severity across East and Southern Africa. The disease progresses from an early (hemo-lymphatic) stage to the late (meningoencephalitic) stage characterized by presence of parasites in the central nervous system. We hypothesized that disease progression and severity of the neurological response is modulated by cytokines. Methods A total of 55 sleeping sickness cases and 41 healthy controls were recruited passively at Lwala hospital, in Northern Uganda. A panel of six cytokines (IFN-γ, IL1-β, TNF-α, IL-6, TGF-β and IL-10) were assayed from paired plasma and cerebrospinal fluid (CSF) samples. Cytokine concentrations were analyzed in relation to disease progression, clinical presentation and severity of neurological responses. Results Median plasma levels (pg/ml) of IFN-γ (46.3), IL-6 (61.7), TGF-β (8755) and IL-10 (256.6) were significantly higher in cases compared to controls (p< 0.0001). When early stage and late stage CSF cytokines were compared, IL-10 and IL-6 were up regulated in late stage patients and were associated with a reduction in tremors and cranioneuropathy. IL-10 had a higher staging accuracy with a sensitivity of 85.7% (95% CI, 63.7%-97%) and a specificity of 100% (95% CI, 39.8%-100%) while for IL-6, a specificity of 100% (95% CI, 47.8%-100%) gave a sensitivity of 83.3% (95% CI, 62.2%-95.3%). Conclusion Our study demonstrates the role of host inflammatory cytokines in modulating the progression and severity of neurological responses in sleeping sickness. We demonstrate here an up-regulation of IL-6 and IL-10 during the late stage with a potential as adjunct stage biomarkers. Given that both cytokines could potentially be elevated by other CNS infections, our findings should be further validated in a large cohort of patients including those with other inflammatory diseases such as cerebral malaria.

References

[1]  Simarro PP, Cecchi G, Franco JR, Paone M, Diarra A, Ruiz-Postigo JA, et al. Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis. 2012; 6: e1859. doi: 10.1371/journal.pntd.0001859. pmid:23145192
[2]  Welburn SC, Fèvre EM, Coleman PG, Odiit M,Maudlin I. Sleeping sickness: a tale of two diseases. Trends Parasitol. 2001; 17: 19–24. pmid:11137736 doi: 10.1016/s1471-4922(00)01839-0
[3]  MacLean L, Chisi JE, Odiit M, Gibson WC, Ferris V, Picozzi K, et al. Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun. 2004; 72: 7040–7044. pmid:15557627 doi: 10.1128/iai.72.12.7040-7044.2004
[4]  MacLean LM, Odiit M, Chisi JE, Kennedy PG,Sternberg JM. Focus–Specific Clinical Profiles in Human African Trypanosomiasis Caused by Trypanosoma brucei rhodesiense. PLoS Negl Trop Dis. 2010; 4: e906. doi: 10.1371/journal.pntd.0000906. pmid:21151878
[5]  MacLean , Odiit M, MacLeod A, Morrison L, Sweeney L, Cooper A, et al. Spatially and genetically distinct African Trypanosome virulence variants defined by host interferon-γ response. J Infect Dis. 2007; 196: 1620–1628. pmid:18008245 doi: 10.1086/522011
[6]  Sternberg JM,MacLean L. A spectrum of disease in human African trypanosomiasis: the host and parasite genetics of virulence. Parasitology. 2010; 137: 2007–2015. doi: 10.1017/S0031182010000946. pmid:20663245
[7]  Kennedy PG. Cytokines in central nervous system trypanosomiasis: cause, effect or both? Trans R Soc Trop Med Hyg. 2009; 103: 213–214. doi: 10.1016/j.trstmh.2008.08.013. pmid:18814893
[8]  Hertz CJ, Filutowicz H,Mansfield JM. Resistance to the African trypanosomes is IFN-γ dependent. J Immunol. 1998; 161: 6775–6783. pmid:9862708
[9]  Russell KL, Ming JE, Patel K, Jukofsky L, Magnusson M,Krantz ID. human and rodent interferon-as a growth factor for trypanosoma brucei. Eur J Immunol. 2005.
[10]  Sternberg JM, Rodgers J, Bradley B, MacLean L, Murray M,Kennedy PG. Meningoencephalitic African trypanosomiasis: brain IL-10 and IL-6 are associated with protection from neuro-inflammatory pathology. J Neuroimmunol. 2005; 167: 81–89. pmid:16054238 doi: 10.1016/j.jneuroim.2005.06.017
[11]  Namangala B, No?l W, De Baetselier P, Brys L,Beschin A. Relative contribution of interferon-γ and interleukin-10 to resistance to murine African trypanosomosis. J Infect Dis. 2001; 183: 1794–1800. pmid:11372033 doi: 10.1086/320731
[12]  Yamey G. Research Ethics and Reporting Standards at PLoS Neglected Tropical Diseases. PLoS Negl Trop Dis. 2007; 1: e69. doi: 10.1371/journal.pntd.0000069
[13]  MacLean L, Odiit M,Sternberg JM. Intrathecal cytokine responses in Trypanosoma brucei rhodesiense sleeping sickness patients. Trans R Soc Trop Med Hyg 2006; 100: 270–275. pmid:16343570 doi: 10.1016/j.trstmh.2005.03.013
[14]  MacLean L, Reiber H, Kennedy PG,Sternberg JM. Stage progression and neurological symptoms in Trypanosoma brucei rhodesiense sleeping sickness: role of the CNS inflammatory response. PLoS Negl Trop Dis. 2012; 6: e1857. doi: 10.1371/journal.pntd.0001857. pmid:23145191
[15]  Chappuis F, Loutan L, Simarro P, Lejon V,Büscher P. Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev. 2005; 18: 133–146. pmid:15653823 doi: 10.1128/cmr.18.1.133-146.2005
[16]  Kennedy PG. Diagnostic and neuropathogenesis issues in human African trypanosomiasis. Int J Parasitol. 2006; 36: 505–512. pmid:16546191 doi: 10.1016/j.ijpara.2006.01.012
[17]  WHO. Control and surveillance of African trypanosomiasis: report of a WHO expert committee. WHO Tech Rep Ser. 2013; 984: 1–250. pmid:24552089
[18]  Balasegaram M, Harris S, Checchi F, Hamel C,Karunakara U. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull World Health Organ. 2006; 84: 777–782. pmid:17128357 doi: 10.2471/blt.05.028399
[19]  Doua F, Miezan T, Sanon SJ, Boa YF,Baltz T. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am J Trop Med Hyg. 1996; 55: 586–588. pmid:9025682
[20]  Ruiz JA, Simarro PP,Josenando T. Control of human African trypanosomiasis in the Quicama focus, Angola. Bull World Health Organ. 2002; 80: 738–745. pmid:12378293
[21]  Hainard A, Tiberti N, Robin X, Lejon V, Ngoyi DM, Matovu E, et al. A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis. 2009; 3: e459. doi: 10.1371/journal.pntd.0000459. pmid:19554086
[22]  Ngotho M, Kagira J, Jensen H, Karanja S, Farah I,Hau J. Immunospecific immunoglobulins and IL‐10 as markers for Trypanosoma brucei rhodesiense late stage disease in experimentally infected vervet monkeys. Trop Med Int Health. 2009; 14: 736–747. doi: 10.1111/j.1365-3156.2009.02285.x. pmid:19573160
[23]  Tiberti N, Matovu E, Hainard A, Enyaru JC, Lejon V, Robin X, et al. New biomarkers for stage determination in Trypanosoma brucei rhodesiense sleeping sickness patients. Clin Transl Med. 2013; 2: 1. doi: 10.1186/2001-1326-2-1. pmid:23369533
[24]  Lejon V, Roger I, Ngoyi DM, Menten J, Robays J, N'Siesi FX, et al. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis. Clin Infect Dis. 2008; 47: 15–22. doi: 10.1086/588668. pmid:18494605
[25]  Rodgers J. Trypanosomiasis and the brain. Parasitology. 2010; 137: 1995–2006. doi: 10.1017/S0031182009991806. pmid:20028610
[26]  Woo P. The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta tropica. 1970; 27: 384–386. pmid:4396363
[27]  Mumba Ngoyi D, Menten J, Pyana PP, Büscher P,Lejon V. Stage determination in sleeping sickness: comparison of two cell counting and two parasite detection techniques. Trop Med Int Health. 2013; 18: 778–782. doi: 10.1111/tmi.12102. pmid:23506188
[28]  Teasdale G,Jennett B. Assessment of coma and impaired consciousness: a practical scale. The Lancet. 1974; 304: 81–84. doi: 10.1016/s0140-6736(74)91639-0
[29]  MacLean L, Odiit M,Sternberg JM. Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis. 2001; 184: 1086–1090. pmid:11574928 doi: 10.1086/323479
[30]  Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian journal of internal medicine. 2013; 4: 627. pmid:24009950
[31]  Buyst H. The epidemiology of sleeping sickness in the historical Luangwa valley. Ann Soc Belg Med Trop. 1977; 57: 349–359. pmid:345980
[32]  Courtin D, Jamonneau V, Mathieu JF, Koffi M, Milet J, Yeminanga CS, et al. Comparison of cytokine plasma levels in human African trypanosomiasis. Trop Med Int Health. 2006; 11: 647–653. pmid:16640617 doi: 10.1111/j.1365-3156.2006.01612.x
[33]  Nyawira Maranga D, Kagira JM, Kinyanjui CK, Muturi Karanja S, Wangari Maina N,Ngotho M. IL-6 is Upregulated in Late-Stage Disease in Monkeys Experimentally Infected with Trypanosoma brucei rhodesiense. Clin Dev Immunol. 2013; 2013. doi: 10.1155/2013/320509
[34]  Lejon V, Lardon J, Kenis G, Pinoges L, Legros D, Bisser S, et al. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg. 2002; 96: 329–333. pmid:12174791 doi: 10.1016/s0035-9203(02)90115-x
[35]  Rhind SG, Sabiston BH, Shek PN, Buguet A, Muanga G, Stanghellini A, et al. Effect of melarsoprol treatment on circulating IL-10 and TNF-α levels in human African trypanosomiasis. Clin Immunol. 1997; 83: 185–189. pmid:9143380 doi: 10.1006/clin.1997.4350
[36]  Kennedy PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol. 2008; 64: 116–126. doi: 10.1002/ana.21429. pmid:18756506
[37]  Enanga B, Burchmore R, Stewart M,Barrett M. Sleeping sickness and the brain. Cell Mol Life Sci. 2002; 59: 845–858. pmid:12088284 doi: 10.1007/s00018-002-8472-0
[38]  Hunter C, Jennings F, Kennedy P,Murray M. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. Lab Inves. 1992; 67: 635–642. pmid:1434541
[39]  Okomo-Assoumou MC, Daulouede S, Lemesre J-L, N'Zila-Mouanda A,Vincendeau P. Correlation of high serum levels of tumor necrosis factor-alpha with disease severity in human African trypanosomiasis. Am J Trop Med Hyg. 1995; 53: 539–543. pmid:7485714
[40]  Ngotho M, Maina N, Kagira J, Royo F, Farah IO,Hau J. IL-10 is up regulated in early and transitional stages in vervet monkeys experimentally infected with Trypanosoma brucei rhodesiense. Parasitol Int. 2006; 55: 243–248. pmid:16901747 doi: 10.1016/j.parint.2006.06.004
[41]  Penkowa M, Giralt M, Lago N, Camats J, Carrasco J, Hernández J, et al. Astrocyte-targeted expression of IL-6 protects the CNSagainst a focal brain injury. Exp Neuro. 2003; 181: 130–148. doi: 10.1016/s0014-4886(02)00051-1
[42]  Courtin D, Milet J, Jamonneau V, Yeminanga CS, Kumeso VKB, Bilengue CMM, et al. Association between human African trypanosomiasis and the IL6gene in a Congolese population. Infect Genet Evol. 2007; 7: 60–68. pmid:16720107 doi: 10.1016/j.meegid.2006.04.001
[43]  Van Wagoner NJ, Oh J-W, Repovic P,Benveniste EN. Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci. 1999; 19: 5236–5244. pmid:10377335
[44]  Oh J-W, Van Wagoner NJ, Rose-John S,Benveniste EN. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J Immunol. 1998; 161: 4992–4999. pmid:9794436
[45]  Wahl SM, McCartney-Francis N,Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-β. Immunol Today. 1989; 10: 258–261. pmid:2478145 doi: 10.1016/0167-5699(89)90136-9
[46]  Kennedy P. Difficulties in diagnostic staging of human African trypanosomiasis. J Neuroparasitol. 2011; 2: 1–3. doi: 10.4303/jnp/n110601
[47]  Kato CD, Nanteza A, Mugasa C, Edyelu A, Matovu E,Alibu VP. Clinical Profiles, Disease Outcome and Co-Morbidities among T. b. rhodesiense Sleeping Sickness Patients in Uganda. PloS one. 2015; 10: e0118370. doi: 10.1371/journal.pone.0118370. pmid:25719539
[48]  Guimar?es da Costa A, do Valle Antonelli LR, Augusto Carvalho Costa P, Paulo Diniz Pimentel J, Garcia NP, Monteiro Tarrag? A, et al. The Robust and Modulated Biomarker Network Elicited by the Plasmodium vivax Infection Is Mainly Mediated by the IL-6/IL-10 Axis and Is Associated with the Parasite Load. J Immunol Res. 2014; 2014. doi: 10.1155/2014/318250

Full-Text

comments powered by Disqus